Dr. Quevedo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1993 - 1994
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1990 - 1993
- Cleveland Clinic FoundationResidency, Internal Medicine, 1987 - 1990
- Cleveland Clinic FoundationInternship, Internal Medicine, 1987 - 1988
- Universidad Catolica de Santiago de GuayaquilClass of 1985
Certifications & Licensure
- FL State Medical License 2022 - 2026
- MN State Medical License 1990 - 2025
- IA State Medical License 2004 - 2008
- IL State Medical License 1996 - 1999
- LA State Medical License 1994 - 1996
- OH State Medical License 1994 - 1996
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Teacher of The Year Mayo Fellows Association, Mayo Clinic College of Medicine
Publications & Presentations
PubMed
- 1 citationsGenomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients.Surendra Dasari, Michael R McCarthy, Antonina A Wojcik, Beth A Pitel, Arpan Samaddar
Prostate Cancer and Prostatic Diseases. 2024-02-27 - 1 citationsThe Impact of Metastasis Histopathology on Oncologic Outcomes for Patients With Surgically Resected Metastatic Renal Cell Carcinoma.Rodrigo Rodrigues Pessoa, Reza Nabavizadeh, Fernando Quevedo, Daniel D Joyce, Christine M Lohse
The Journal of Urology. 2023-10-01 - Dynamic assessment of serum chromogranin A and treatment response with abiraterone acetate in metastatic castration-resistant prostate cancer.Akeem R Lewis, Brian A Costello, Fernando Quevedo, Lance C Pagliaro, Cristobal Sanhueza
The Prostate. 2023-05-01
Journal Articles
- Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution ExperienceSio TT, Wilson ZC, Stauder MC, Bhatia S, Martenson JA, Quevedo JF, Schomas DA, Miller RC, Am J Clin Oncol, 5/1/2013
- Malignant perivascular epithelioid cell tumor of the uterusBleeker JS, Quevedo JF, Folpe AL, Rare Tumors, 1/1/2012
- "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategiesBleeker JS, Quevedo JF, Folpe AL, Sarcoma, 1/1/2012
- Join now to see all
Abstracts/Posters
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study.Aleksandar S, Migden M, Basset-Seguin N, Garbe C, Gesierich A, Lao C, Miller C, Mortier L, Murrell D, Hamid O, Quevedo JF, Mackey H, Schadendorf D, ASCO, 1/1/2013
- Concurrent chemotherapy and intensity modulated radiation therapy (IMRT) in the treatment of anal cancer: a retrospective review from a large academic center.Call J, Haddock M, Quevedo JF, David L, Miller R, American Journal Of Clinical Oncology-cancer Clinical Trials, 4/1/2011
- Down-staging of locally advanced prostate cancer with anti-CTLA-4 monoclonal antibody prior to radical prostatectomy.Granberg C, Thompson RH, Quevedo JF, Karnes RJ, Frank I, Kwon ED, Blute ML, J Clin Oncol, 5/1/2009
- Join now to see all
Lectures
- Long-term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: Final Update (30-month) of the Pivotal ERIVANCE BCC Study.Chicago, IL - 6/1/2014
- GU CancersLima, Peru - 8/1/2012
- Colon CancerCuenca, Ecuador - 7/1/2012
- Join now to see all
Press Mentions
- Physics Institute Focused on Developing Countries Gets a New LeaderNovember 14th, 2019
- CUI, ICTP to Collaborate in MathsSeptember 16th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: